Five Agendia abstracts have been accepted, including two poster spotlight presentations and one late-breaking poster. The ...

Illumina (ILMN) will release TruSight Oncology 500 v2, a new version of its flagship cancer research assay to enable comprehensive genomic ...

TruSight Oncology portfolio enables clinical research and in-vitro diagnostic CGP solutions ...

NEW YORK, Nov. 16, 2024 /PRNewswire/ -- Experts from NYU Langone Heart will present the latest advancements in cardiovascular ...

Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies.

including five accepted abstracts for poster presentation and participation in the workshop “From Data to Decisions: The Potential of RWE Transportability in Healthcare Decision Making.” ...

ProCaB (Prospective Sample Collection for Cancer of Bladder) is a single-center non-interventional, prospective study recruiting all eligible patients diagnosed with BC in a tertiary center in the ...

The meeting had a record high of 1,003 attendees from 39 countries who participated in 35 sessions, including 219 abstract posters and 57 educational exhibits. This expert analysis reviews the high ...

Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster ...

- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS Initial data from the dose escalation phase using a July 15, 2024 data cutoff date indicate that ...